Streetbeat News

FENC

Fennec Pharmaceuticals Inc.

https://www.fennecpharma.com

Industry

Biotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Open

4.04

Mkt cap

111M

Volume

58K

High

4.11

P/E Ratio

-100.87

52-wk high

11.92

Low

4.01

Div yield

N/A

52-wk low

3.96

Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference, with management available for one-on-one meetings.

Portfolio Pulse from

November 13, 2024 | 11:45 am

Fennec Pharmaceuticals Inc. held its Q3 2024 earnings call, providing updates on its financial performance and corporate activities.

Portfolio Pulse from

November 10, 2024 | 3:45 am

Adherex Technologies Inc. (FENC) reported a Q3 loss of $0.21 per share, missing the Zacks Consensus Estimate of a $0.13 loss. This is a larger loss compared to $0.07 per share a year ago.

Portfolio Pulse from

November 07, 2024 | 1:45 pm

Fennec Pharmaceuticals reported Q3 2024 financial results with $7 million in net product sales. The company is seeing increased momentum in the AYA segment due to strategic investments. Fennec has strengthened its leadership team and has $40 million in cash to fund operations until at least 2026.

Portfolio Pulse from

November 07, 2024 | 11:30 am

HC Wainwright & Co. has maintained a Buy rating on Fennec Pharmaceuticals but lowered the price target from $15 to $13.